Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

EFICAC-TTR-tutkimus: Liikunta ja ravintolisävalmisteet transityretiiniamyloidoosin sydämen sairaudessa (EFICAC-TTR)

tiistai 22. syyskuuta 2026 päivittänyt: Universidad de Burgos

Prospektiivinen, satunnaistettu, monikeskuksinen kliininen tutkimus kotipohjaisen monikomponenttisen liikuntaohjelman ja ravintolisien yhdistelmän vaikutuksesta transityretiini-sydämen amyloidoosipotilaille

Transthyretin cardiac amyloidosis (TTR-CA) is a systemic cardiac disease that predominantly affects older adults and is frequently associated with reduced physical capacity, muscle weakness, frailty, and impaired quality of life. Although disease-modifying treatments can slow cardiac disease progression, functional and nutritional impairment remain important unmet clinical needs.

EFICAC-TTR is a prospective, randomized, multicenter study designed to evaluate the effects of a 12-week home-based multicomponent exercise program combined with nutritional supplementation in adults aged 70 years or older with confirmed TTR-CA.

A total of 47 participants were randomized to one of three parallel groups: (1) usual medical care; (2) a home-based multicomponent exercise program plus microcrystalline cellulose control supplementation; or (3) the same exercise program plus creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

The primary functional outcomes are change in 6-minute walk test distance and handgrip strength from baseline to 12 weeks. Secondary outcomes include body composition, frailty, quality of life, and nutritional and clinical variables. Mechanistic biomarkers are assessed as exploratory outcomes.

The study aims to determine whether combining exercise with nutritional supplementation can improve functional capacity and related health outcomes in older adults with TTR-CA.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Participants were randomized to three parallel study groups. The usual-care group continued standard clinical management without a structured exercise program or study supplementation. Participants in the two exercise groups performed the same 12-week home-based multicomponent exercise program adapted to individual functional capacity.

In addition to exercise, one group received daily microcrystalline cellulose as a control supplement, whereas the experimental group received creatine monohydrate (3 g/day) plus beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day). The supplement comparison was blinded, while the comparison with usual care was necessarily open because of the behavioral intervention. Functional outcomes were assessed at baseline and after 12 weeks.

Biological samples collected at baseline and after the intervention are used for exploratory mechanistic analyses.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

47

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Castille and León
      • Aranda de Duero, Castille and León, Espanja
        • Hospital Santos Reyes
      • Burgos, Castille and León, Espanja, 09006
        • Hospital Universitario de Burgos
      • Soria, Castille and León, Espanja
        • Hospital Santa Bárbara

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

70 vuotta ja vanhemmat (Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Age ≥70 years.
  • Confirmed diagnosis of transthyretin cardiac amyloidosis (TTR-CA) based on positive bone scintigraphy with diphosphonates (Perugini grade 2 or 3) and absence of monoclonal protein.
  • Clinical stability during the 4 weeks prior to enrollment.
  • Ability to understand the study procedures and provide written informed consent.

Exclusion Criteria:

  • Light-chain (AL) amyloidosis or other non-TTR amyloidosis variants.
  • Absolute medical contraindication to moderate-intensity exercise.
  • Severe comorbid conditions with an estimated life expectancy <6 months.
  • Severe cognitive impairment (Mini-Mental State Examination score <20).
  • Concurrent participation in another clinical trial or structured exercise program.
  • Known allergy or intolerance to creatine, beta-hydroxy-beta-methylbutyrate (HMB), or microcrystalline cellulose.
  • Severe renal impairment requiring dialysis.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Muut: Usual Care

Participants received usual medical care for transthyretin cardiac amyloidosis, including routine cardiology follow-up and general lifestyle and nutritional recommendations, without the structured study exercise program or study supplementation.

Standard clinical management for transthyretin cardiac amyloidosis according to routine cardiology practice.

Placebo Comparator: Exercise + Microcrystalline Cellulose Control Supplementation

Participants performed a 12-week home-based multicomponent exercise program and received daily microcrystalline cellulose as the control supplement. The supplement was provided in sachets matched to the supplementation procedure used in the experimental arm.

A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.

Daily oral supplementation with microcrystalline cellulose, used as a nutritionally inert control supplement to match supplementation procedures.

Kokeellinen: Exercise + Creatine and HMB Supplementation

Participants performed the same 12-week home-based multicomponent exercise program and received daily supplementation with creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.

Daily oral supplementation with creatine monohydrate (3 g/day) and β-hydroxy-β-methylbutyrate (HMB, 3 g/day) for 12 weeks.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Handgrip Strength
Aikaikkuna: Baseline and 12 weeks

Change in maximal isometric handgrip strength measured in kilograms (kg) using a calibrated handheld dynamometer (best of three attempts for the dominant hand), expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in 6-Minute Walk Test Distance
Aikaikkuna: Baseline and 12 weeks

Change in walking capacity assessed by the 6-minute walk test, measured as the difference in total distance walked (meters) between baseline and 12 weeks.

Baseline and 12 weeks

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Fat Mass
Aikaikkuna: Baseline and 12 weeks

Change in total body fat mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Skeletal Muscle Mass
Aikaikkuna: Baseline and 12 weeks

Change in skeletal muscle mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Fat-Free Mass
Aikaikkuna: Baseline and 12 weeks

Change in fat-free mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Phase Angle
Aikaikkuna: Baseline and 12 weeks

Change in phase angle measured in degrees (°) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Frailty Status Assessed by the FRAIL Scale
Aikaikkuna: Baseline and 12 weeks

Change in frailty status assessed by the FRAIL scale, a 5-item questionnaire with scores ranging from 0 to 5, where higher scores indicate greater frailty, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Short Physical Performance Battery (SPPB) Score
Aikaikkuna: Baseline and 12 weeks

Change in Short Physical Performance Battery (SPPB) total score, ranging from 0 to 12 points, where higher scores indicate better physical performance, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Clinical Frailty Scale (CFS) Score
Aikaikkuna: Baseline and 12 weeks

Change in frailty severity assessed by the Clinical Frailty Scale (CFS), a 9-point ordinal scale ranging from 1 (very fit) to 9 (terminally ill), where higher scores indicate greater frailty.

Baseline and 12 weeks
Change in Barthel Index Score
Aikaikkuna: Baseline and 12 weeks

Change in functional independence assessed by the Barthel Index, scored from 0 to 100, where higher scores indicate greater independence.

Baseline and 12 weeks
Change in SARC-F Score
Aikaikkuna: Baseline and 12 weeks

Change in sarcopenia risk assessed by the SARC-F questionnaire, with scores ranging from 0 to 10, where higher scores indicate greater sarcopenia risk.

Baseline and 12 weeks
Change in Minnesota Living With Heart Failure Questionnaire Score
Aikaikkuna: Baseline and 12 weeks

Change in health-related quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ), with total scores ranging from 0 to 105, where higher scores indicate worse quality of life.

Baseline and 12 weeks
Change in Charlson Comorbidity Index
Aikaikkuna: Baseline and 12 weeks

Change in comorbidity burden assessed using the Charlson Comorbidity Index, a weighted index that accounts for the number and severity of comorbid conditions, where higher scores indicate greater comorbidity burden.

Baseline and 12 weeks
Exercise Program Adherence
Aikaikkuna: Up to 12 weeks

Proportion (%) of prescribed exercise sessions completed, with adequate adherence defined as completion of at least 80% of prescribed sessions.

Up to 12 weeks
Supplement Adherence
Aikaikkuna: Up to 12 weeks

Proportion (%) of planned supplement doses consumed, with optimal compliance defined as 90-110%.

Up to 12 weeks
Change in Mini Nutritional Assessment Short-Form (MNA-SF) Score
Aikaikkuna: Baseline and 12 weeks

Change in nutritional status assessed by the Mini Nutritional Assessment Short-Form (MNA-SF), with scores ranging from 0 to 14 points, where lower scores indicate poorer nutritional status and greater risk of malnutrition.

Baseline and 12 weeks
Incidence of Intervention-Related Adverse Events
Aikaikkuna: Up to 12 weeks

Number and type of adverse events related to exercise and/or supplementation, classified according to severity and relatedness, collected during the 12-week intervention period.

Up to 12 weeks
Rate of Supplement Discontinuation
Aikaikkuna: Up to 12 weeks

Proportion of participants who discontinue study supplementation during the intervention period.

Up to 12 weeks
Change in Skeletal Muscle Index (SMI)
Aikaikkuna: Baseline and 12 weeks

Change in skeletal muscle index (SMI), expressed as skeletal muscle mass normalized to height squared (kg/m²), measured using multifrequency bioelectrical impedance analysis, between baseline and 12 weeks.

Baseline and 12 weeks

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Growth Differentiation Factor 15 (GDF-15)
Aikaikkuna: Baseline and 12 weeks

Change in serum GDF-15 concentration (ng/mL) measured by immunoassay.

Baseline and 12 weeks
Change in Soluble ST2
Aikaikkuna: Baseline and 12 weeks

Change in serum soluble ST2 concentration (ng/mL) measured by immunoassay.

Baseline and 12 weeks
Change in Interleukin-6 (IL-6)
Aikaikkuna: Baseline and 12 weeks

Change in serum interleukin-6 (IL-6) concentration (pg/mL) measured by immunoassay.

Baseline and 12 weeks
Change in C-Reactive Protein (CRP)
Aikaikkuna: Baseline and 12 weeks

Change in serum C-reactive protein (CRP) concentration (mg/dL) measured by immunoassay.

Baseline and 12 weeks
Change in circulating miR-21 expression
Aikaikkuna: Baseline and 12 weeks

Change in circulating miR-21 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-29 expression
Aikaikkuna: Baseline and 12 weeks

Change in circulating miR-29 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-34a expression
Aikaikkuna: Baseline and 12 weeks

Change in circulating miR-34a expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-155 expression
Aikaikkuna: Baseline and 12 weeks

Change in circulating miR-155 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in PBMC Immune Polarization Profile by Flow Cytometry
Aikaikkuna: Baseline and 12 weeks

Change in the immunophenotypic profile of peripheral blood mononuclear cells (PBMCs) assessed by multiparametric flow cytometry, including the relative abundance of cell populations with M1-like and M2-like phenotypes and their ratio.

Baseline and 12 weeks
Change in Pro-inflammatory (M1) Gene Expression Markers
Aikaikkuna: Baseline and 12 weeks

Change in gene expression of predefined pro-inflammatory (M1-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in Anti-inflammatory (M2) Gene Expression Markers
Aikaikkuna: Baseline and 12 weeks

Change in gene expression of predefined anti-inflammatory/regenerative (M2-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in Serum Albumin
Aikaikkuna: Baseline and 12 weeks

Change in serum albumin concentration (g/dL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Serum Prealbumin
Aikaikkuna: Baseline and 12 weeks

Change in serum prealbumin concentration (g/dL) between baseline and 12 weeks

Baseline and 12 weeks
Change in Vitamin D
Aikaikkuna: Baseline and 12 weeks

Change in serum 25-hydroxyvitamin D concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Galectin-3
Aikaikkuna: Baseline and 12 weeks

Change in serum galectin-3 concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in NT-proBNP
Aikaikkuna: Baseline and 12 weeks

Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration (pg/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in High-Sensitivity Troponin T
Aikaikkuna: Baseline and 12 weeks

Change in serum high-sensitivity cardiac troponin T concentration (ng/L) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Leptin
Aikaikkuna: Baseline and 12 weeks

Change in serum leptin concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Adiponectin
Aikaikkuna: Baseline and 12 weeks

Change in serum adiponectin concentration (µg/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in IGF-1
Aikaikkuna: Baseline and 12 weeks

Change in serum insulin-like growth factor 1 (IGF-1) concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Klotho
Aikaikkuna: Baseline and 12 weeks

Change in serum Klotho concentration (pg/mL) between baseline and 12 weeks.

Baseline and 12 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Yhteistyökumppanit

Tutkijat

  • Opintojohtaja: Juan Mielgo-Ayuso, PhD, Universidad de Burgos
  • Päätutkija: José A Pérez Rivera, PhD, MD, Hospital Universitario de Burgos

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 3. helmikuuta 2026

Ensisijainen valmistuminen (Todellinen)

Torstai 10. syyskuuta 2026

Opintojen valmistuminen (Todellinen)

Torstai 10. syyskuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 17. joulukuuta 2025

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 7. tammikuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Torstai 15. tammikuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 25. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 22. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

De-identified individual participant data that underlie the results reported in publications will be made available upon reasonable request.

IPD-jaon aikakehys

Beginning 6 months after publication and ending 5 years after publication.

IPD-jaon käyttöoikeuskriteerit

Access to de-identified individual participant data will be granted upon reasonable request to the principal investigator. Requests must include a methodologically sound research proposal and will be evaluated for scientific merit and feasibility. Data sharing will require the execution of a data sharing agreement and will comply with applicable data protection and privacy regulations.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa